Kevin C. Tang Buys 22,810 Shares of Odonate Therapeutics Inc (ODT) Stock
Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang acquired 22,810 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were purchased at an average cost of $18.93 per share, with a total value of $431,793.30. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Odonate Therapeutics stock opened at $19.75 on Friday. The company has a market capitalization of $511.75 million and a P/E ratio of -8.55. Odonate Therapeutics Inc has a fifty-two week low of $15.15 and a fifty-two week high of $32.00.
Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings results on Monday, July 30th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.03. research analysts expect that Odonate Therapeutics Inc will post -3.42 EPS for the current year.
Several institutional investors have recently modified their holdings of ODT. Janus Henderson Group PLC increased its holdings in shares of Odonate Therapeutics by 472.8% in the second quarter. Janus Henderson Group PLC now owns 1,074,348 shares of the company’s stock valued at $23,722,000 after purchasing an additional 886,794 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Odonate Therapeutics in the first quarter valued at approximately $6,018,000. Tang Capital Management LLC increased its holdings in shares of Odonate Therapeutics by 1.7% in the first quarter. Tang Capital Management LLC now owns 12,412,338 shares of the company’s stock valued at $262,893,000 after purchasing an additional 210,000 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Odonate Therapeutics in the fourth quarter valued at approximately $2,277,000. Finally, Northern Trust Corp acquired a new stake in shares of Odonate Therapeutics in the first quarter valued at approximately $1,489,000. 83.42% of the stock is owned by institutional investors and hedge funds.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Featured Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.